Hematopoiesis News 9.21 May 29, 2018 | |
| |
TOP STORYA System of Check and Balances in the Blood To compensate for blood loss, HSCs, which are usually dormant, start to actively self-renew and differentiate into all blood cell types. After completing their task, however, HSCs need to revert back to their dormant state very rapidly, or they will exhaust. This requires a very delicate balance. [Press release from Universität Wien discussing online prepublication in Cell Stem Cell] Press Release | Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Because models involving erythroid differentiation of CD34+ cells have limitations in assessing γ-globin re-activation, scientists focused on human β-globin locus transgenic (β-YAC) mice. They demonstrated efficient target site disruption resulting in a pronounced switch from human β- to γ-globin expression in red blood cells of adult mice that was maintained after secondary transplantation of hematopoietic stem/progenitor cells. [Blood] Abstract GPIbα Is Required for Platelet-Mediated Hepatic Thrombopoietin Generation Researchers revealed a novel non-redundant regulatory role of platelets in hepatic thrombopoietin (TPO) homeostasis, which not only improves the understanding of constitutive TPO regulation but also has important implications in diseases related to GPIbα such as Bernard-Soulier Syndrome and auto- and alloimmune-mediated thrombocytopenias. [Blood] Abstract The authors showed that activation of the arterial program through ETS1 overexpression or by modulating MAPK/ERK signaling pathways at the mesodermal stage of development dramatically enhanced the formation of arterial-type hemogenic endothelium expressing DLL4 and CXCR4. [Cell Rep] Full Article | Graphical Abstract Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome Researchers demonstrated the ability of both the transcription activator-like effector nuclease and clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) platforms to efficiently drive integration of a normal copy of the CD40L cDNA delivered by adeno-associated virus. [Cell Rep] Full Article | Graphical Abstract Hematopoietic Stem Cells as a Novel Source of Dental Tissue Cells Scientists utilized a unique transgenic model in which all hematopoietic cells are green fluorescent protein+ (GFP+). Transplantation of clonal population derived from a single GFP+ HSC, into lethally irradiated recipient mice, demonstrated numerous GFP+ cells within dental tissues of recipient mice, which also stained for markers of cell populations in pulp, periodontal ligament and alveolar bone indicating that transplanted HSCs can differentiate into cells in dental tissues. [Sci Rep] Full Article The authors demonstrated that mesenchymal progenitor-like cells expressing Tlx1, an essential transcription factor for spleen organogenesis, and selectively localized in the perifollicular region of the red pulp of the spleen, are a major source of hematopoietic stem/progenitor cell niche factors. [Sci Rep] Full Article CLINICAL RESEARCHResearchers identified the recommended Phase II dose of clofarabine replacing fludarabine in a combination regimen. Clofarabine was well tolerated and showed high response rates in relapsed/refractory pediatric acute myeloid leukemia. [Haematologica] Abstract | Full Article The authors report results on the prospective and extensive dissection of the hematopoietic hierarchy in 20 patients with either low-risk myelodysplastic syndromes (MDS) or MDS with excess blasts and compare it to hematopoiesis in patients with non-malignancy-associated cytopenia or B cell lymphoma without bone marrow infiltration. [PLoS One] Full Article CD7 Is Expressed on a Subset of Normal CD34-Positive Myeloid Precursors To improve monitoring of myeloid neoplasms by flow cytometry‐based minimal residual disease analysis, investigators analyzed the significance of leukemia‐associated immunophenotype markers in 44 patients. [Eur J Haematol] Abstract | |
| |
REVIEWSHematopoietic Stem Cell Fate through Metabolic Control A deeper understanding of precisely how specific modes of metabolism control HSC fate at the single cell level is not only of great biological interest, but will have clear clinical implications for the development of therapies for hematological disease. [Exp Hematol] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSNohla Therapeutics announced the online availability of an abstract that has been selected for presentation. The abstract summarizes long-term follow-up data showing that Nohla’s NLA101 cell therapy significantly improved hematopoietic recovery with no patients experiencing transplant-related mortality, leading to an 86% disease-free and overall survival rate in patients undergoing a cord blood transplant. [Press release from Nohla Therapeutics (GlobeNewswire, Inc.) discussing research to be presented at the 23rd Congress of European Hematology Association Annual Conference, Stockholm] Press Release MaxCyte announced that Linghong Li, PhD, Director, Cell Engineering, presented pre-clinical data in which MaxCyte’s non-viral cell engineering technology was used for CRISPR-mediated gene-correction of a mutation within the hemoglobin gene of cells from a sickle cell disease patient. [Press release from MaxCyte discussing research presented at the 2018 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), Chicago] Press Release | |
| |
INDUSTRY NEWSAdaptive Biotechnologies announced that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease status in response to isatuximab. [Adaptive Biotechnologies] Press Release Oncolytics Biotech® Inc. announced a collaboration with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda®, Velcade® and dexamethasone, to treat multiple myeloma. [Oncolytics Biotech, Inc.] Press Release Astellas Pharma Inc. announced that the FDA has accepted, with Priority Review, the company’s New Drug Application for gilteritinib for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test. [Astellas Pharma Inc.] Press Release AbbVie announced that the Phase III iLLUMINATE trial met its primary endpoint of improvement in progression-free survival. [AbbVie (PR Newswire Association LLC.)] Press Release Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma Genmab A/S announced that topline results from the Phase III study of Arzerra® plus bendamustine did not meet the primary endpoint of improved progression-free survival in patients with indolent B-cell non-Hodgkin’s lymphoma who were unresponsive to rituximab or a rituximab-containing regimen, compared to those given bendamustine alone. [Genmab A/S] Press Release | |
| |
POLICY NEWSItaly’s New Prime Minister Defended Discredited Stem Cell Therapy The electoral victory of two populist parties in March had Italian scientists worried that a new era of antiscientific policies might be around the corner—and appointment of Giuseppe Conte as the country’s new prime minister is making some even more nervous. [ScienceInsider] Editorial Scientist Who Received Millions from NIH Leaves Alabama Posts A professor who received about $5 million in grants from the National Institutes of Health left his posts at the University of Alabama, Birmingham, and Birmingham VA Medical Center last year after an investigation found evidence of image manipulation in 20 of his papers, Retraction Watch has learned. [The Scientist] Editorial
| |
EVENTSNEW 2nd AACR International Conference: Translational Cancer Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Research Scholar – Hematologic Malignancies (Washington University School of Medicine) Postdoctoral Position – Hematology (Yale University) Director – Josep Carreras Leukaemia Research Institute (Josep Carreras Leukaemia Research Institute) Cancer Researchers – Hematologic Malignancy (Cedars-Sinai Medical Center) Postdoctoral Fellow – Hematopoiesis and Leukemia (University of Pennsylvania) Group Leader – Leukemia Research (Hospital del Mar Research Institute) Postdoctoral Position – Leukemia Research (Oslo Universitetssykehus HF) Postdoctoral Fellow – B-Cell Lymphoma (University of Texas Health Science Center at San Antonio) Postdoctoral Position – Stem Cell and Cancer Research (Institute for Research in Biomedicine) Postdoctoral Associate – Leukemia (St. Jude Children’s Research Hospital) Postdoctoral Associate – Stem Cell Biology and Cancer Epigenetics (The Jackson Laboratory) Postdoctoral Fellow – Stem Cells, Development & Cancer (Albert Einstein College of Medicine) Postdoctoral Research Associate – Mechanisms of Leukemia (University of Virginia) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|